Filtered By:
Source: American Heart Journal
Condition: Diabetes Type 2
Drug: Zivast
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
Publication date: Available online 9 August 2019Source: American Heart JournalAuthor(s): Kausik K. Ray, Stephen J. Nicholls, Henry Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Peter P. Toth, Norman Wong, Jeffrey L. Cummings, Michael Sweeney, Gregory G. SchwartzAbstractBackgroundAfter an acute coronary syndrome (ACS), patients with diabetes remain at high risk for additional cardiovascular events despite use of current therapies. Bromodomain and extra-terminal (BET) proteins are epigenetic modulators of inflammation, thrombogenesis, and lipoprotein metabolism implicated in atherothrombosis. The BET...
Source: American Heart Journal - August 9, 2019 Category: Cardiology Source Type: research
